PF-04929113 (SNX-5422) is orally bioavailable heat shock protein 90 (Hsp90) inhibitor.

PF-04929113 (SNX-5422) is orally bioavailable heat shock protein 90 (Hsp90) inhibitor.

PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2.

PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2.

PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2.

PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor.

PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor.

PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor.

PF-06447475 is a highly potent, selective, brain penetrant LRRK2 inhibitor with IC0 of 3 nM/11 nM for Wt LRRK2/G2019S LRRK2 respectively.

PF-06447475 is a highly potent, selective, brain penetrant LRRK2 inhibitor with IC0 of 3 nM/11 nM for Wt LRRK2/G2019S LRRK2 respectively.

PF-06447475 is a highly potent, selective, brain penetrant LRRK2 inhibitor with IC0 of 3 nM/11 nM for Wt LRRK2/G2019S LRRK2 respectively.

PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of

PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of

PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of

RG3039 (PF-06687859) is orally bioavailable, brain-penetrant small molecule that has been shown to be an inhibitor of the mRNA decapping enzyme, DcpS.

RG3039 (PF-06687859) is orally bioavailable, brain-penetrant small molecule that has been shown to be an inhibitor of the mRNA decapping enzyme, DcpS.

RG3039 (PF-06687859) is orally bioavailable, brain-penetrant small molecule that has been shown to be an inhibitor of the mRNA decapping enzyme, DcpS.

PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).

PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).

PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).

PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).

PF-2545920 is a phosphodiesterase inhibitor selective for the PDE10A subtype.

PF-2545920 is a phosphodiesterase inhibitor selective for the PDE10A subtype.

PF-2545920 is a phosphodiesterase inhibitor selective for the PDE10A subtype.

PF-2545920 is a phosphodiesterase inhibitor selective for the PDE10A subtype.

PF-3635659 is a potent muscarinic M(3) receptor antagonists.

PF-3635659 is a potent muscarinic M(3) receptor antagonists.

PF-3635659 is a potent muscarinic M(3) receptor antagonists.

PF-3758309 is a small-molecule p21-activated kinase inhibitor inhibiting oncogenic signaling and tumor growth.

PF-3758309 is a small-molecule p21-activated kinase inhibitor inhibiting oncogenic signaling and tumor growth.

PF-3758309 is a small-molecule p21-activated kinase inhibitor inhibiting oncogenic signaling and tumor growth.

PF-3758309 is a small-molecule p21-activated kinase inhibitor inhibiting oncogenic signaling and tumor growth.

PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It reduces inflammatory pain via a cannabinoid receptor-dependent mechanism.

PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It reduces inflammatory pain via a cannabinoid receptor-dependent mechanism.

PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It reduces inflammatory pain via a cannabinoid receptor-dependent mechanism.

PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796.

PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796.

PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796.

PF-5274857 is a novel Smo antagonist that specifically binds to Smo with a K(i) of 4.6 ?? 1.1 nmol/L and completely blocks the transcriptional activity of the downstream gene Gli1 with an IC(50) of 2.7 ?? 1.4 nmol/L in cells.

PF-5274857 is a novel Smo antagonist that specifically binds to Smo with a K(i) of 4.6 ?? 1.1 nmol/L and completely blocks the transcriptional activity of the downstream gene Gli1 with an IC(50) of 2.7 ?? 1.4 nmol/L in cells.

PF-5274857 is a novel Smo antagonist that specifically binds to Smo with a K(i) of 4.6 ?? 1.1 nmol/L and completely blocks the transcriptional activity of the downstream gene Gli1 with an IC(50) of 2.7 ?? 1.4 nmol/L in cells.

PF-5274857 is a novel Smo antagonist that specifically binds to Smo with a K(i) of 4.6 ?? 1.1 nmol/L and completely blocks the transcriptional activity of the downstream gene Gli1 with an IC(50) of 2.7 ?? 1.4 nmol/L in cells.

PF-543 is a novel selective SK-1 inhibitor which inhibited SK-1 activity in a competitive manner with sphingosine.

PF-543 is a novel selective SK-1 inhibitor which inhibited SK-1 activity in a competitive manner with sphingosine.

PF-543 is a novel selective SK-1 inhibitor which inhibited SK-1 activity in a competitive manner with sphingosine.